Related Experiment Video
Updated: Sep 11, 2025
11:42
Combination of Microstereolithography and Electrospinning to Produce Membranes Equipped with Niches for Corneal Regeneration
Published on: September 12, 2014
12.6K
Transforming Human Amniotic Membrane into Nanoparticles: An Approach for Cardiac Delivery Systems.
Austin Stellpflug1, Siqi Li2,3, Tina Wan2,3
1Joint Department of Biomedical Engineering, Marquette University and the Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
ACS Applied Bio Materials
|August 11, 2025
Summary
Researchers developed amniotic membrane-derived nanoparticles (AMPs) for targeted heart repair. These biocompatible AMPs efficiently deliver drugs to cardiac tissue, offering a safer, more effective approach to treating heart failure.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Cardiovascular Research
Background:
- Cardiovascular disease is a leading cause of death, with heart failure presenting a significant therapeutic challenge.
- Current treatments for heart failure have limitations, necessitating novel strategies for cardiac repair and regeneration.
- Nanoparticles offer potential for targeted drug delivery, enhancing efficacy and reducing side effects in cardiac therapies.
Purpose of the Study:
- To develop and evaluate amniotic membrane-derived nanoparticles (AMPs) as a platform for targeted cardiac drug delivery.
- To assess the physicochemical properties, drug-loading capacity, and biocompatibility of AMPs.
- To investigate the efficacy and retention of AMPs in cardiac tissue for potential heart failure treatment.
Main Methods:
- Decellularized human amniotic membrane (DAM) was used to fabricate amniotic membrane-derived nanoparticles (AMPs).
- Physicochemical properties including size, surface charge, and drug-release kinetics were characterized.
- Encapsulation efficiency was assessed using a fluorescent dye, followed by in vitro and in vivo biocompatibility and cardiac tissue retention studies.
Main Results:
- AMPs demonstrated nanoscale dimensions, a mild positive surface charge, and sustained drug release.
- Efficient drug-loading capacity was confirmed, with potential for noninvasive imaging.
- In vitro and in vivo studies showed excellent biocompatibility, minimal cytotoxicity, no inflammatory response, and superior cardiac tissue retention compared to free agents.
Conclusions:
- AMPs derived from decellularized amniotic membrane represent a promising, biocompatible platform for cardiac drug delivery.
- AMPs offer targeted delivery, controlled release, and enhanced retention in cardiac tissue, addressing key challenges in heart failure therapy.
- This nanotechnology provides a foundation for developing next-generation, minimally invasive therapies for cardiovascular diseases.
